Bristol Myers Squibb Says Its Phase 2 LATTICE-UC Study Did Not Meet Primary Objective

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) on Thursday said its Phase 2 study of deucravacitinib dubbed LATTICE-UC in moderate to severe ulcerative colitis (UC) did not meet the primary

Related Keywords

Samit Hirawat ,Bristol Myers Squibb ,Myers Squibb ,Bristol Myers ,Bristol ,Myers ,Squibb ,Ways ,Hase ,Lattice ,Study ,Feet ,Primary ,Objective ,